Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Elicio Therapeutics, Inc. (ELTX) Discusses Camupepimut Development in Neoadjuvant and Metastatic Pancreatic Cancer Transcript
Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC
Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting
Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
ELTX Investors Have Opportunity to Join Elicio Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
Elicio Therapeutics Points To Durable Responses As It Maps Next Steps For Lead Cancer Drug
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer